Below is a selection of educational resources, including Immunexpress sponsored webinar presentations and podcasts and sepsis information from authoritative advocacy groups and international health agencies, such as the Centers for Disease Control and Prevention (CDC) and National Institutes Health (NIH) and the open access journal JAMA Network.
Resources
Sepsis and Wound Care Global Congress, 2025
“Host-Response Sepsis Diagnostic Test Demonstrating High Predictive Probability of Sepsis.”
Identifying Patients in the Sepsis Gray Zone
Identifying Patients in the Sepsis Gray Zone is a free, accredited CME course designed to strengthen clinical judgment in the early identification of sepsis, the leading cause of death in hospitals.
The series equips clinicians with concrete tools to act confidently in the ambiguous early stages of sepsis: the Sepsis Gray Zone.
In addition to earning a CME for each of the course’s three modules, course participants who complete all three modules will receive a “Certification in Sepsis Diagnosis.” .
The Physician-Patient Alliance for Health & Safety produced these courses with educational grants from Immunexpress and Thermo Fisher Scientific.
Module 1 – Foundations of Sepsis Diagnosis and the Role of Lactate
This module serves as a “level-set,” establishing a shared mindset and language around sepsis detection.
Key themes include:
- The physiological cascade sepsis triggers, revisiting what’s happening inside the body
- The rationale behind the Three- and Six-Hour Bundles of sepsis care, and when “Time Zero” actually begins
- The importance of collaboration across healthcare disciplines and settings
Module 2 – Advances in Sepsis Diagnosis and Clinical Research
Module 2 brings course participants up to speed on the latest clinical trial research.
Key themes include:
- The use of biomarkers, such as lactic acid and procalcitonin, in sepsis diagnosis
- The mindset to contextualize diagnostic tools so that they are not used as a “one-size-fits-all” approach
- The judgment necessary to support antibiotic stewardship without compromising patient care
Module 3 – Navigating the Gray Zone of Sepsis Diagnosis
The final module begins with an overview of the SeptiCyte RAPID test, then guides participants through classic presentations of sepsis to put their clinical reasoning to the test.
Key themes include:
- The appropriate use of SeptiCyte RAPID to distinguish sepsis from non-infectious systemic inflammation
- The value of sepsis care that is supported by tools and tests, but not dependent on them
- The key interventions most effective to prevent further patient decompensation
Sepsis Proability, Antibiotic Stewardship, and Precision Medicine Using SeptiCyte® RAPID. Presented by Presentation by Dr Russ Miller, MD, MPH, FCCM FirstHealth of the Carolinas. April 30, 2025
The role of a host response test, Septicyte Rapid, to improve sepsis bundle compliance and address diagnostic uncertainty. Presented by Dr. Roy Davis, chief medical officer at Immunexpress, and Dr. Russell Miller, medical director of critical care at FirstHealth of the Carolinas.
Dr. Ramzy Rimawi, Assistant Professor of Medicine at Emory University Hospital, discusses the potential impact of SeptiCyte RAPID on sepsis bundle compliancy
At the Sepsis Alliance AMR Conference, on April 26th 2023, Dr Aslam, from Cone Moses Hospital described a study looking at antibiotic administration, bundle compliance and the impact of SeptiCyte RAPID, an FDA cleared host response assay to differentiate sepsis from non-infectious systemic inflammation.
Three European speakers describe case studies with SeptiCyte RAPID, including a burn patient, a patient with an abscess post abdominal surgery and a patient with nosocomial infection
In this webinar Dr. Kenneth Remy speaks to the current challenges associated with diagnosing sepsis and describes new approaches with technologies that harness the host’s immune response to infection leading to sepsis.
He illustrates how these new technologies can provide a prompter and more precise assessment of the suspected sepsis patient to guide the physician in care management decisions and how a Quality Improvement (QI) Initiative can provide a mechanism to evaluate and introduce them to your hospital sepsis program.
This webinar, hosted by Biocartis, covers the role and utility of a host response test, SeptiCyte® RAPID in clinical scenarios of suspected sepsis patients and the resulting sepsis diagnosis. Two of the speakers present SeptiCyte® RAPID case reports and a third speaker describes an evaluation in a cohort of burn patients. The presenters are:
– Prof Marc VASSE, Head of the Biology Department, Foch Hospital, Suresnes, France
– Dr François Dépret, Associate Professor in Burn ICU, APHP, St Louis Hospital, Paris, France
– José Garnacho-Montero, MD, PhD, Director of Intensive Care Clinical Unit, University Hospital Virgen Macarena, Sevilla, Spain
In this presentation entitled, “A host response test to address the challenges of early sepsis diagnosis,” Dr. Robert Balk, Professor in the Department of Internal Medicine at Rush Medical College and Dr. Roy Davis, Chief Medical Officer of Immunexpress, discussed sepsis and the current challenges of sepsis diagnosis. Dr. Balk explained the burden of sepsis, the challenge of diagnosing sepsis, the benefits of rapid diagnosis and shared performance data from the clinical validation study of SeptiCyte® RAPID, which recently received FDA clearance. Dr. Davis explained the challenges in diagnostic differentiation and the risk of under- or over-treating patients suspected of sepsis. He presented two case studies and reviewed how SeptiCyte® RAPID aligns with the new 2021 guidelines for sepsis clinical management from the Surviving Sepsis Campaign.
Roy Davis, M.D., Ph.D., MHA, Chief Medical Officer of Immunexpress, discussed differentiating sepsis from non-infectious systemic inflammation using FDA-cleared SeptiCyte® RAPID, a one-hour gene expression assay, in this webinar hosted by Biocartis. In this webinar, Dr. Davis explained the challenges in this diagnostic differentiation and the risk of under- or over-treating patients suspected of sepsis. He reviewed the clinical validation data for SeptiCyte® RAPID and how this host response test could assist with diagnostic uncertainty and impact the early initiation of appropriate therapy and outcome. Additionally, Dr. Davis reviews how SeptiCyte® RAPID aligns with the new 2021 guidelines for sepsis clinical management from the Surviving Sepsis Campaign.
Roy Davis, M.D., Ph.D., MHA, Chief Medical Officer of Immunexpress, presented an educational webinar hosted by Biocartis focused on SeptiCyte® RAPID in COVID-19 patients suspected of sepsis. In this webinar, Dr. Davis discussed the similarities between bacterial sepsis and severe COVID-19 illness, reviewed the data supporting SeptiCyte® RAPID for risk stratification of COVID-19 patients suspected of sepsis including a comparison to other biomarkers, and presented case studies that illustrate how SeptiCyte® RAPID could address the challenge of triaging COVID-19 patients.
A Podcast on Differentiating between Sepsis and SIRS
In this podcast, Dr. Annette Esper, Assoc. Prof of Medicine at Emory University School of Medicine and Medical Director of step-down ICU at Grady Memorial Hospital, describes the challenges associated with differentiating between sepsis and infection negative systemic inflammation in sepsis patients with varying levels of clinical suspicion and probability. Furthermore, she addresses the dilemma of under or over-treating suspected sepsis patients in order to comply with CMS SEP-1 quality metrics and follow the new SSC clinical management guidelines for sepsis. She also outlines how the newly FDA-cleared SeptiCyte® RAPID test, might assist with this diagnostic uncertainty and impact early appropriate therapy and outcomes in the ICU.
In this webinar, hosted by Biocartis, Dr. Roy Davis reviews SeptiCyte® technology and its clinical validation in peer-reviewed journals and a correlation study of FDA cleared SeptiCyte® LAB with the 2nd generation, SeptiCyte® RAPID, which runs on Idylla™, generating results in 1 hr. Additionally, he presents recent data for the performance of SeptiCyte® RAPID in various patient cohorts, including candidemia, immunocompromised, oncology and COVID-19
Dr. Roy Davis provides an overview of the current challenges of sepsis diagnosis and management, specifically related to early identification and appropriate intervention. He describes how the host immune response can be leveraged by including a gene expression assay as part of the Sepsis Clinical Toolset. The proposed role for this assay in the clinical workflow and sepsis program triage is covered along with its impact on diagnostic uncertainty.
A Podcast on Severe COVID-19 and Sepsis
Severe COVID-19 infection can be a form of viral sepsis with occasionally concomitant bacterial infection. Pamela M. Peeke MD, MPH, FACP, FACSM, is joined by Russell Miller, MD, MPH, FCCM, to discuss the definition of sepsis and overlap with case descriptions of patients with severe COVID-19, how experience with viral sepsis can be leveraged to diagnose and treat COVID-19 patients being admitted to ICU, and the need to be able to differentiate viral from bacterial sepsis to avoid over or under treatment. Dr. Miller is medical director of critical care at FirstHealth of the Carolinas in Pinehurst, North Carolina, USA.
A Podcast on Sepsis Quality Improvement Program Components
Effectively addressing bacterial, fungal and viral sepsis requires a collaborative approach, with early identification and intervention being central to improving outcomes. Yet several barriers remain to building an effective sepsis quality improvement program. Host Michael Smith, MD, along with Erkan Hassan, PharmD, FCCM, and Roy Davis, MD, PhD, MHA, explores the specific components of a sepsis improvement program that healthcare professionals and hospitals must consider. Dr. Hassan is a principal of Transformational Views Consulting Group and cofounder and chief clinical officer of Sepsis Program Optimization. Dr. Davis is chief medical officer of Immunexpress Inc.
This webinar, given by Dr. Roy Davis, Chief Medical Officer of Immunexpress, addresses the shortcomings of past and current sepsis clinical criteria in accurately capturing patients with critical illness due to infection. The current status of microbiologic methods and single peptide biomarker will be described. A novel approach utilizing the host gene response to infection, SeptiCyte®, will be presented.
